Enfusion (ENFN) 10-Q 13 May 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 12, 2022
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-40949
Entity Registrant Name	Enfusion, Inc
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-1268462
Entity Address State Or Province	IL
Entity Address, Address Line One	125 South Clark Street
Entity Address, Address Line Two	Suite 750
Entity Address, City or Town	Chicago
Entity Address, Postal Zip Code	60603
City Area Code	312
Local Phone Number	253-9800
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Title of 12(b) Security	Class A common stock, par value $0.001per share
Trading Symbol	ENFN
Security Exchange Name	NYSE
Entity Central Index Key	0001868912
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Amendment Flag	false
Common Class A
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		65,583,289
Common Class B
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		47,470,971

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current Assets:
Cash	$ 56,206	$ 64,365
Accounts receivable, net	23,410	18,223
Prepaid expenses	5,458	6,030
Other current assets	1,332	1,060
Total current assets	86,406	89,678
Property and equipment, net	15,046	13,051
Other assets	3,499	3,356
Total assets	104,951	106,085
Current liabilities:
Accounts payable	1,189	2,528
Accrued expenses and other current liabilities	6,557	5,578
Total current liabilities	7,746	8,106
Other liabilities	497	538
Total liabilities	8,243	8,644
Commitments and contingencies
Stockholders' Equity:
Additional paid-in capital	233,607	226,717
Accumulated deficit	(178,474)	(171,209)
Accumulated other comprehensive loss	(375)	(325)
Total stockholders' equity attributable to Enfusion, Inc.	54,871	55,296
Non-Controlling Interests	41,837	42,145
Total stockholders' equity	96,708	97,441
Total liabilities and stockholders' equity	104,951	106,085
Common Class A
Stockholders' Equity:
Common stock	66	66
Common Class B
Stockholders' Equity:
Common stock	$ 47	$ 47

Condensed Consolidated Interi_2

Condensed Consolidated Interim Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Common Class A
Common stock par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	65,583,289	65,583,289
Common stock, shares outstanding	65,583,289	65,583,289
Common Class B
Common stock par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	47,470,971	47,470,971
Common stock, shares outstanding	47,470,971	47,470,971

Condensed Consolidated Interi_3

Condensed Consolidated Interim Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
REVENUES:
Total revenues	$ 34,141	$ 24,353
COST OF REVENUES:
Total cost of revenues	10,983	6,809
Gross profit	23,158	17,544
OPERATING EXPENSES:
General and administrative	22,295	6,381
Sales and marketing	8,432	3,158
Technology and development	4,802	2,202
Total operating expenses	35,529	11,741
(Loss) income from operations	(12,371)	5,803
NON-OPERATING INCOME (EXPENSE):
Interest expense	(6)	(1,392)
Other income (expense)	3
Total non-operating income (expense)	(3)	(1,392)
(Loss) income before income taxes	(12,374)	4,411
Income taxes	150	302
Net (loss) income	(12,524)	4,109
Net loss attributable to non-controlling interests	(5,259)
Net loss attributable to Enfusion, Inc.	$ (7,265)	4,109
Net loss per Class A common shares attributable to Enfusion, Inc.:
Net loss per Class A common shares attributable to Enfusion, Inc., Basic	$ (0.10)
Net loss per Class A common shares attributable to Enfusion, Inc., Diluted	$ (0.10)
Weighted Average number of Class A common shares outstanding:
Weighted Average number of Class A common shares outstanding, Basic	83,384
Weighted Average number of Class A common shares outstanding, Diluted	83,384
Platform subscriptions
REVENUES:
Total revenues	$ 31,551	22,423
COST OF REVENUES:
Total cost of revenues	9,311	5,952
Managed services
REVENUES:
Total revenues	2,230	1,534
COST OF REVENUES:
Total cost of revenues	1,615	828
Other
REVENUES:
Total revenues	360	396
COST OF REVENUES:
Total cost of revenues	$ 57	$ 29

Condensed Consolidated Interi_4

Condensed Consolidated Interim Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Condensed Consolidated Interim Statements of Comprehensive (Loss) Income
Net (loss) income	$ (12,524)	$ 4,109
Other comprehensive loss, net of income tax:
Foreign currency translation loss	(86)	(61)
Total other comprehensive (loss) income	(12,610)	4,048
Comprehensive loss attributable to non-controlling interests	(5,295)
Total comprehensive (loss) income attributable to Enfusion, Inc.	$ (7,315)	$ 4,048

Condensed Consolidated Interi_5

Condensed Consolidated Interim Statements of Preferred Units, Stockholders' Equity and Members' Deficit - USD ($) $ in Thousands	Preferred Units	Members' Equity	Common StockCommon Class A	Common StockCommon Class B	Additional Paid-in Capital	Accumulated Deficit/Retained Earnings	Accumulated Other Comprehensive Loss	Noncontrolling Interest	Total
Balance at Beginning of period at Dec. 31, 2020							$ (212)		$ (233,559)
Balance at Beginning of period at Dec. 31, 2020		$ (233,347)
Balance at Beginning of period (in shares) at Dec. 31, 2020		47.968
Members' Equity (Deficit)
Net Income (Loss)		$ 1,937							1,937
Foreign currency translation loss							(61)		(61)
Balance at end of period at Mar. 31, 2021		$ (231,410)
Balance at end of period at Mar. 31, 2021							(273)		(231,683)
Balance at end of period (in shares) at Mar. 31, 2021		47.968
Balance at Beginning of period at Dec. 31, 2020	$ 165,515
Balance at Beginning of period (in shares) at Dec. 31, 2020	53.774
Preferred Units
Net income	$ 2,172
Distributions to members	(164)
Balance at end of period at Mar. 31, 2021	$ 167,523
Balance at end of period (in shares) at Mar. 31, 2021	53.774
Balance at Beginning of period at Dec. 31, 2020							(212)		(233,559)
Balance at Beginning of period at Dec. 31, 2020		$ (233,347)
Balance at Beginning of period (in shares) at Dec. 31, 2020		47.968
Balance at end of period at Dec. 31, 2021			$ 66	$ 47	$ 226,717	$ (171,209)	(325)	$ 42,145	97,441
Balance at end of period (in shares) at Dec. 31, 2021			65,583,289	47,470,971
Balance at Beginning of period at Dec. 31, 2020	$ 165,515
Balance at Beginning of period (in shares) at Dec. 31, 2020	53.774
Members' Equity (Deficit)
Net Income (Loss)						(7,265)		(5,259)	(12,524)
Share-based compensation, net of taxes paid					6,890			4,987	11,877
Foreign currency translation loss							(50)	(36)	(86)
Balance at end of period at Mar. 31, 2022			$ 66	$ 47	$ 233,607	$ (178,474)	$ (375)	$ 41,837	$ 96,708
Balance at end of period (in shares) at Mar. 31, 2022			65,583,289	47,470,971

Condensed Consolidated Interi_6

Condensed Consolidated Interim Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net (loss) income	$ (12,524)	$ 4,109
Adjustments to reconcile Net (loss) income to Net cash provided by operating activities:
Depreciation and amortization	1,340	755
Provision for bad debts	123	87
Amortization of debt-related costs	6	74
Stock-based compensation expense	12,682
Change in operating assets and liabilities:
Accounts receivable	(5,310)	(1,751)
Prepaid expenses and other current assets	(13)	(659)
Accounts payable	(1,339)	66
Accrued expenses and other liabilities	938	(1,914)
Net cash (used) provided by operating activities	(4,097)	767
Cash flows from investing activities:
Purchases of property and equipment	(3,171)	(2,352)
Net cash used in investing activities	(3,171)	(2,352)
Cash flows from financing activities:
Payment of Member distributions		(164)
Payment of withholding taxes on stock-based compensation	(805)
Net cash used in financing activities	(805)	(164)
Effect of exchange rate changes on cash	(86)	(61)
Net decrease in cash	(8,159)	(1,810)
Cash, beginning of period	64,365	13,938
Cash, end of period	56,206	12,128
Supplemental disclosure of cash flow information:
Interest paid in cash		1,342
Income taxes paid in cash	$ 265	$ 118

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2022
Organization and Description of Business
Organization and Description of Business	Note 1 Organization and Description of Business Enfusion, Inc. (“Enfusion” or the “Company”) is a leading provider of cloud-based order and execution management, portfolio management and risk systems. Enfusion’s clients include large global hedge fund managers, institutional asset managers, family offices and other institutional investors. Enfusion provides its clients with innovative real-time performance, risk calculations, and accounting capabilities for some of the most sophisticated financial products. The Company is headquartered in Chicago, Illinois and has offices in Chicago, New York, London, Dublin, Hong Kong, Singapore, São Paulo, Mumbai, Bengaluru, and Sydney. Enfusion, Inc. was incorporated in Delaware on June 11, 2021 for the purpose of facilitating an initial public offering which was completed on October 25, 2021, and other related transactions in order to carry on the business of Enfusion Ltd. LLC. Enfusion, Inc. now has three wholly-owned subsidiaries: Enfusion US1, Inc., Enfusion US2, Inc. and Enfusion US3, Inc.; as well as a substantial financial interest in Enfusion Ltd. LLC and its wholly-owned subsidiaries: Enfusion Systems UK Ltd, Enfusion HK Limited, Enfusion Software Limited, Enfusion Softech India Private Limited, Enfusion (Singapore) Pte. Ltd., Enfusion do Brasil Tecnologia da Informacao Ltda, Enfusion (Australia) Pty. Ltd. and Enfusion (Shanghai) Co., Ltd. Enfusion, Inc., through its control over the managing member of Enfusion Ltd. LLC, manages and operates Enfusion Ltd. LLC’s business and controls its strategic decisions and day-to-day operations. As such, Enfusion, Inc. consolidates the financial results of Enfusion Ltd. LLC, and a portion of Enfusion, Inc.’s net income will be allocated to non-controlling interests to reflect the entitlement of the Pre-IPO Common Unitholders to a portion of Enfusion Ltd. LLC’s net income. As of March 31, 2022, we owned approximately 58% of Enfusion Ltd. LLC.

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2022
Basis of Presentation
Basis of Presentation	Note 2 Basis of Presentation Principles of Consolidation These statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and in accordance with rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, the financial statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments necessary for a fair presentation of our financial position and results of operations, and all adjustments are of a normal recurring nature. The operating results for the three months ended March 31, 2022 are not necessarily indicative of the results expected for the full year ending December 31, 2022. The condensed consolidated financial information should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The unaudited condensed consolidated financial statements include the accounts of Enfusion, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions are eliminated in consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The effect of the change in the estimates will be recognized in the current period of the change.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 3 Summary of Significant Accounting Policies A description of the Company’s significant accounting policies is included in the audited financial statements within its Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes in the Company’s significant accounting policies during the three months ended March 31, 2022. ​ Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. The Company derives its revenues primarily from fees for platform subscription and managed services provided to clients. Revenues are recognized when control of these services are transferred to the Company’s clients in an amount that reflects the consideration the Company expects to be entitled to in exchange for these services. Revenues are recognized net of taxes that will be remitted to governmental agencies applicable to service contacts. Historically, platform subscription contracts have typically had a one-year term and were cancellable with 30 days’ notice, though our more recent contracts have typically been for multi-year terms without cancellation for convenience. Clients are invoiced each month for the services provided in accordance with the stated terms of their service contracts. Fees for partial term service contracts are prorated, as applicable. Payment of fees are due from clients within 30 days of the invoice date. The Company does not provide financing to clients. The Company determines revenue recognition through the following five-step framework: ● Identification of the contract, or contracts, with a client; ● Identification of the performance obligation in the contract; ● Determination of transaction price; ● Allocation of the transaction price to the performance obligations in the contract; and ● Recognition of revenue when, or as, performance obligations are satisfied. Platform subscription revenues Platform subscription revenues consist primarily of fees for providing clients with access to the Company’s cloud-based platform. Platform subscription clients do not have the right to take possession of the platform’s software, and do not have any general return rights. Platform subscription revenues are generally recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date that the client gains access to the platform. Installment payments are invoiced at the end of each calendar month during the subscription term. Managed services revenues Managed services revenues primarily consist of client-selected middle and back-office services provided on our clients’ behalf using the Company’s platform. Revenue is recognized monthly as the managed services are performed, with invoicing occurring at the end of the calendar month. Other revenues Other revenues consists of non-subscription-based revenues, such as software enhancements developed for individual, sponsoring clients, but received by all clients, and data conversion and services that integrate a client’s historical data into our solution. We recognize revenues monthly as these services are performed with invoicing occurring at the end of each month. Service contracts with multiple performance obligations Our service contracts with clients can include multiple performance obligations. For these contracts, we account for individual performance obligations separately if they are distinct. However, all distinct performance obligations within a contract are satisfied over a similar period of time with the same measure of progress. Accordingly, each distinct performance obligation within a contract has the same pattern of revenue recognition. We have determined that implementation services are not distinct from the ongoing platform subscription services due to the highly specialized knowledge required to execute on our solution. Such services are recognized with the platform subscription services revenue over time. Remaining performance obligations For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of March 31, 2022 was $28.8 million. The Company expects to recognize this amount over the next one Disaggregation of revenue The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following table (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ ​ 2022 ​ 2021 ​ Geographic Region ​ Amount Percent Amount Percent Americas* ​ $ 21,938 64.3 % $ 16,258 66.8 % ​ Europe, Middle East and Africa (EMEA) ​ 4,310 12.6 % 2,713 11.1 % ​ Asia Pacific (APAC) ​ 7,893 23.1 % 5,382 22.1 % ​ Total revenues ​ $ 34,141 100.0 % $ 24,353 100.0 % ​ ​ * The Company’s total revenues in the United States were $21.5 million and $16.0 million for the three months ended March 31, 2022 and 2021, respectively. Accounts Receivable As of March 31, 2022 and December 31, 2021, no individual client represented more than 10% of accounts receivable. For the three months ended March 31, 2022 and 2021, respectively, no individual client represented more than 10% of the Company’s total revenues. Recent Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU 2016-02 , Leases Leases Codification Improvements to Topic 842, Leases Leases In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses Measurement of Credit Losses on Financial Instruments In December 2019, the FASB issued ASU 2019-12, Income Taxes Simplifying the Accounting for Income Taxes

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2022
Property and Equipment, Net
Property and Equipment, Net	Note 4 Property and Equipment, Net Property and equipment, net consists of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 December 31, 2021 ​ Computer equipment and software ​ $ 16,134 ​ $ 14,163 ​ Software development costs ​ 6,072 ​ 4,866 ​ Leasehold improvements ​ 1,936 ​ 1,947 ​ Furniture and fixtures ​ 545 ​ 540 ​ Total property and equipment, cost ​ 24,687 ​ 21,516 ​ Less accumulated depreciation and amortization ​ (9,641) ​ (8,465) ​ Total property and equipment, net ​ $ 15,046 ​ $ 13,051 ​ ​ As of March 31, 2022 and December 31, 2021, property and equipment, net located in the United States was $12.2 million and $10.4 million, respectively. The remainder was located in our various international locations. Included in property and equipment are the capitalized costs of software development. Software development costs capitalized during the three months ended March 31, 2022 and 2021 were $1.2 million and $499 thousand, respectively. Depreciation and amortization expense related to property and equipment, excluding software development costs, was $768 thousand and $484 thousand for the three months ended March 31, 2022 and 2021, respectively. Amortization expense related to software development costs was $408 thousand and $272 thousand for the three months ended March 31, 2022 and 2021, respectively.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2022
Accrued Expenses and Other Current Liabilities
Accrued Expenses and Other Current Liabilities	Note 5 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 December 31, 2021 ​ Accrued compensation ​ $ 3,973 ​ $ 3,180 ​ Accrued expenses ​ 1,973 ​ 1,182 ​ Accrued taxes ​ 611 ​ 1,216 ​ Total accrued expenses and other current liabilities ​ $ 6,557 ​ $ 5,578 ​ ​

Operating Leases and Service Ag

Operating Leases and Service Agreements	3 Months Ended
	Mar. 31, 2022
Operating Leases and Service Agreements
Operating Leases and Service Agreements	Note 6 Operating Leases and Service Agreements Operating Leases ​ The Company leases office space in various locations under operating lease agreements in the normal course of business, which expire at various dates through 2025. Certain operating leases are secured with cash security deposits or letters of credit. ​ Service Agreements ​ The Company has service agreements for the use of data processing facilities. These service agreements expire at various dates through 2023. Monthly base payments as of March 31, 2022 range from $6 thousand to $16 thousand. Future aggregate minimum rental payments under the noncancelable operating leases and service agreements noted above, excluding the Company’s share of real estate taxes and other operating costs, are as follows (in thousands): ​ ​ ​ ​ ​ ​ Amount 2022 (nine months) ​ $ 3,478 2023 ​ 3,310 2024 ​ 2,385 2025 ​ 901 Total ​ $ 10,074 ​ Total expense related to these lease agreements was $1.0 million and $902 thousand for the three months ended March 31, 2022 and 2021, respectively and is included in Cost of revenues and Operating expenses. Total expense related to the service agreements was $268 and $208 thousand for the three months ended March 31, 2022 and 2021, respectively, and is included in Cost of revenues.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies
Commitments and Contingencies	Note 7 Commitments and Contingencies The Company records accruals for contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated based on historical claim activity and loss development factors. No accruals for contingencies were recorded as of March 31, 2022 and December 31, 2021, respectively.

Preferred Units, Stockholders'

Preferred Units, Stockholders' Equity and Members' Deficit	3 Months Ended
	Mar. 31, 2022
Preferred Units, Stockholders' Equity and Members' Deficit
Preferred Units, Stockholders' Equity and Members' Deficit	Note 8 Preferred Units, Stockholders’ Equity and Members’ Deficit Prior to the Reorganization Transactions, Enfusion Ltd. LLC was organized as a limited liability company owned by its members, each of whose membership interests consisted of an equal number of: (i) “Economic Units”, which represented a Member’s economic interest in Enfusion Ltd. LLC; and (ii) “Participation Units”, which represented a Member’s right to participate (vote) in the affairs of Enfusion Ltd. LLC. As a limited liability company, the Enfusion Ltd. LLC issued more than one class of Units. The Class A Units were considered to be Members’ Equity, whereas all of the other Unit classes were considered to be Preferred Units because of provisions in the Company’s former Operating Agreement that conferred certain rights and privileges to the members owning these Units, such as voting rights, redemption rights and liquidation preferences. Holders of the Class C-1, C-2 and D Preferred Units had the option to require the Company to redeem their Units. In accordance with the guidance in ASC 480, Distinguishing Liabilities from Equity In connection with the Reorganization Transactions, the Amended and Restated Operating Agreement of Enfusion Ltd. LLC (the “LLC Operating Agreement”) was amended and restated to, among other things, modify its capital structure by reclassifying each of the outstanding Class A Units and C-1, C-2 and D Preferred Units into a new class of LLC interests (or “Common Units”) through a stock split on a 1,000,000 to 1 basis. The number of Common Units outstanding following the Reorganization Transaction reflect the 1,000,000 to 1 stock split. Pursuant to the adoption of the LLC Operating Agreement, Enfusion US 1, Inc., a newly-formed wholly owned subsidiary of Enfusion, Inc., was appointed the sole managing member of Enfusion Ltd. LLC. Amendment and Restatement of Certificate of Incorporation In October 2021, the Company amended its certificate of incorporation. The amended and restated certificate of incorporation of Enfusion, Inc. provides for 1,000,000,000 authorized shares of Class A common stock, 150,000,000 authorized shares of Class B common stock and 100,000,000 shares of preferred stock. Each share of our Class A common stock is entitled to one vote per share and is not convertible into any other shares of our capital stock. Holders of shares of our Class A common stock are entitled to receive dividends when, as and if declared by our board of directors. Upon our liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors, and subject to the rights of the holders of one or more outstanding series of preferred stock, as applicable, having liquidation preferences, the holders of shares of our Class A common stock will be entitled to receive pro rata our remaining assets available for distribution. Each share of our Class B common stock is entitled to one vote per share and is not convertible or exchangeable for a share of Class A common stock or any other security. Holders of our Class B common stock do not have any right to receive dividends or to receive a distribution upon a liquidation, dissolution or winding up of Enfusion, Inc. Preferred Stock Our board of directors have the authority, without further action by our stockholders, to issue up to 100,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Class A common stock. As of March 31, 2022, the Company has not issued any shares of preferred stock nor has our board of directors established the rights and privileges related to any series of preferred stock.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2022
Stock-Based Compensation
Stock-Based Compensation	Note 9 The Company recognized total stock compensation expense for the three months ended March 31, 2022 of $12.7 million. In connection with obligations to issue Class A common stock to former holders of Award Units under our former Change in Control Bonus Plan, the Company paid approximately $1.2 million of tax withholding obligations for federal and state payroll taxes. Of that amount, $805 thousand related to employee payroll tax withholdings and has accordingly been recorded as a reduction to Additional Paid-In Capital. The Company’s stock compensation expense was recognized in the following captions within the consolidated statements of operations: ​ ​ ​ ​ ​ (in thousands) ​ Cost of revenues ​ $ 354 General and administrative ​ ​ 8,938 Sales and marketing ​ ​ 1,993 Technology and development ​ ​ 1,397 Total stock compensation expense ​ $ 12,682 ​ Total unrecognized stock compensation expense related to unvested RSUs and Contingently Issuable Shares of Class A stock was $41.1 million as of March 31, 2022, which is expected to be recognized over a weighted-average period of 2 years. In connection with the IPO, the Company also adopted the 2021 Employee Stock Purchase Plan (“2021 ESPP”). Under the 2021 ESPP, eligible employees may be granted options to purchase shares of Class A common stock at the lower of 85% of the fair market value of the stock at the time of grant or 85% of the fair market value at the time of exercise. As of March 31, 2022, no options were granted to employees under the 2021 ESPP.

Net Income (Loss) Per Class A C

Net Income (Loss) Per Class A Common Share	3 Months Ended
	Mar. 31, 2022
Net Income (Loss) Per Class A Common Share
Net Income (Loss) Per Class A Common Share	Note 10 Net Income (Loss) Per Class A Common Share Basic loss per share is computed by dividing net loss attributable to Enfusion, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. Prior to the IPO, the Enfusion, LLC membership structure included Common Units and multiple classes of Preferred Units. The Company analyzed the calculation of earnings per unit for periods prior to the IPO using the two-class method and determined that it resulted in values that would not be meaningful to the users of these Condensed Consolidated Financial Statements. Therefore, earnings per share information has not been presented for periods prior to the IPO on October 20, 2021. A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows: ​ ​ ​ ​ ​ ​ ​ ​ (in thousands, except per share amounts) Three Months Ended March 31, 2022 Numerator: ​ ​ ​ Net loss ​ $ (12,524) Less: Net loss attributable to non-controlling interests ​ ​ 5,259 Net loss attributable to Enfusion, Inc. ​ ​ (7,265) Adjustment to income (loss) attributable to common stockholders ​ ​ (716) Numerator for Basic Earnings per Share ​ $ (7,981) Denominator: ​ ​ ​ Weighted-average shares of Class A common stock outstanding ​ ​ 65,583 Vested shares of Class A common stock and RSUs ​ ​ 17,801 Weighted-average shares of Class A common stock outstanding--basic ​ ​ 83,384 Net loss per share of Class A common stock--basic and diluted ​ $ (0.10) ​ The following number of potentially dilutive shares were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive: ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Three Months Ended March 31, 2022 Class B common stock ​ 47,471 Contingently issuable shares of Class A common stock ​ ​ 893 Restricted stock units ​ ​ 2,857 ​ ​ ​ 51,221 ​ Shares of Class B common stock do not share in earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been presented. Shares of Class B common stock are, however, considered potentially dilutive shares of Class A common stock. After evaluating the potential dilutive effect under both the treasury stock method and if-converted method, shares of Class B common stock were determined to be anti-dilutive and have therefore been excluded from the computation of diluted earnings per share of Class A common stock.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Taxes
Income Taxes	Note 11 Income Taxes The Company is taxed as a corporation for income tax purposes and is subject to federal, state, and local taxes on the income allocated to it from Enfusion Ltd. LLC based upon the Company’s economic interest in Enfusion Ltd. LLC. The Company is the sole managing member of Enfusion Ltd. LLC and, as a result, consolidates the financial results of Enfusion Ltd. LLC. Enfusion Ltd. LLC. is a limited liability company taxed as a partnership for income tax purposes. Enfusion Ltd. LLC does not pay any federal income taxes, as income or loss is included in the tax returns of the individual members. Additionally, certain wholly-owned entities taxed as corporations are subject to federal, state, and foreign income taxes in the jurisdictions in which they operate, and accruals for such taxes are included in the Condensed Consolidated Financial Statements. For periods prior to the IPO, the Company’s taxes represent those of Enfusion Ltd. LLC. The Company’s effective tax rate for the three months ended March 31, 2022 and 2021 was (1.21)% and 6.42% , respectively. In the period ending March 31, 2022, the Company’s effective tax rate differed from the U.S. statutory tax rate of 21% primarily due to non-controlling interest and having a full-valuation allowance in the U.S. Conversely, in the period ending March 31, 2021, the Company’s effective tax rate differed from the U.S. statutory tax rate of 21% primarily due to the pass-through income generated.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions
Related Party Transactions	Note 12 Related Party Transactions Parties are considered to be related if one party has the ability to control or exercise significant influence over the other party in making financial or operating decisions. Since transactions with related parties may raise potential or actual conflicts of interest between the related party and the Company, upon the completion of the IPO the Company implemented a related party transaction policy that requires related party transactions to be reviewed and approved by its nominating and corporate governance committee. The Company used the proceeds (net of underwriting discounts) from the issuance of 5,526,608 million shares in the IPO ($87.8 million) to purchase an equivalent number of Common Units from the Company’s Pre-IPO Common Unitholders. In connection with the IPO, the Company entered into the Tax Receivable Agreement with the Pre-IPO LLC Members, which provides for the payment by Enfusion Inc. of 85% of certain cash tax benefits that Enfusion, Inc. actually realizes, or in some cases is deemed to realize. As of March 31, 2022 and December 31, 2021, the Company has not recorded a liability under the Tax Receivable Agreement related to the tax benefits originating from the Reorganization Transactions, IPO and subsequent purchase of Enfusion Ltd. LLC units during the year ended December 31, 2021 as it is not probable that the Company will realize such tax benefits. To the extent we had determined that we would have been able to realize the tax benefits associated with the basis adjustments, we would have recorded a liability under the Tax Receivable Agreement of $74.7 million as of both March 31, 2022 and December 31, 2021.

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2022
Subsequent Event
Subsequent Event	Note 13 Subsequent Event On May 6, 2022, a Pre-IPO Common Unitholder delivered an exchange notice pursuant to Article XII of the LLC Operating Agreement, relating to the exchange of 1,401,818 Common Units and an equal number of shares of class B common stock for an equal number of Class A common shares. Pursuant to the terms of the LLC Operating Agreement, the Pre-IPO Common Unitholder will surrender 1,401,818 Common Units and an equal number of shares of class B common stock. In connection therewith, the Company will issue 1,401,818 shares of class A common stock to such Pre-IPO Common Unitholder, cancel an equal number of Class B Common Stock, and receive an equal number of common units, increasing the Company’s ownership of Common Units by 1,401,818 .

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Summary of Significant Accounting Policies
Principles of Consolidation	Principles of Consolidation These statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and in accordance with rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, the financial statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments necessary for a fair presentation of our financial position and results of operations, and all adjustments are of a normal recurring nature. The operating results for the three months ended March 31, 2022 are not necessarily indicative of the results expected for the full year ending December 31, 2022. The condensed consolidated financial information should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The unaudited condensed consolidated financial statements include the accounts of Enfusion, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions are eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The effect of the change in the estimates will be recognized in the current period of the change.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. The Company derives its revenues primarily from fees for platform subscription and managed services provided to clients. Revenues are recognized when control of these services are transferred to the Company’s clients in an amount that reflects the consideration the Company expects to be entitled to in exchange for these services. Revenues are recognized net of taxes that will be remitted to governmental agencies applicable to service contacts. Historically, platform subscription contracts have typically had a one-year term and were cancellable with 30 days’ notice, though our more recent contracts have typically been for multi-year terms without cancellation for convenience. Clients are invoiced each month for the services provided in accordance with the stated terms of their service contracts. Fees for partial term service contracts are prorated, as applicable. Payment of fees are due from clients within 30 days of the invoice date. The Company does not provide financing to clients. The Company determines revenue recognition through the following five-step framework: ● Identification of the contract, or contracts, with a client; ● Identification of the performance obligation in the contract; ● Determination of transaction price; ● Allocation of the transaction price to the performance obligations in the contract; and ● Recognition of revenue when, or as, performance obligations are satisfied. Platform subscription revenues Platform subscription revenues consist primarily of fees for providing clients with access to the Company’s cloud-based platform. Platform subscription clients do not have the right to take possession of the platform’s software, and do not have any general return rights. Platform subscription revenues are generally recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date that the client gains access to the platform. Installment payments are invoiced at the end of each calendar month during the subscription term. Managed services revenues Managed services revenues primarily consist of client-selected middle and back-office services provided on our clients’ behalf using the Company’s platform. Revenue is recognized monthly as the managed services are performed, with invoicing occurring at the end of the calendar month. Other revenues Other revenues consists of non-subscription-based revenues, such as software enhancements developed for individual, sponsoring clients, but received by all clients, and data conversion and services that integrate a client’s historical data into our solution. We recognize revenues monthly as these services are performed with invoicing occurring at the end of each month. Service contracts with multiple performance obligations Our service contracts with clients can include multiple performance obligations. For these contracts, we account for individual performance obligations separately if they are distinct. However, all distinct performance obligations within a contract are satisfied over a similar period of time with the same measure of progress. Accordingly, each distinct performance obligation within a contract has the same pattern of revenue recognition. We have determined that implementation services are not distinct from the ongoing platform subscription services due to the highly specialized knowledge required to execute on our solution. Such services are recognized with the platform subscription services revenue over time. Remaining performance obligations For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of March 31, 2022 was $28.8 million. The Company expects to recognize this amount over the next one Disaggregation of revenue The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following table (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ ​ 2022 ​ 2021 ​ Geographic Region ​ Amount Percent Amount Percent Americas* ​ $ 21,938 64.3 % $ 16,258 66.8 % ​ Europe, Middle East and Africa (EMEA) ​ 4,310 12.6 % 2,713 11.1 % ​ Asia Pacific (APAC) ​ 7,893 23.1 % 5,382 22.1 % ​ Total revenues ​ $ 34,141 100.0 % $ 24,353 100.0 % ​ ​ * The Company’s total revenues in the United States were $21.5 million and $16.0 million for the three months ended March 31, 2022 and 2021, respectively.
Accounts Receivable	Accounts Receivable As of March 31, 2022 and December 31, 2021, no individual client represented more than 10% of accounts receivable. For the three months ended March 31, 2022 and 2021, respectively, no individual client represented more than 10% of the Company’s total revenues.
Recent Accounting Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU 2016-02 , Leases Leases Codification Improvements to Topic 842, Leases Leases In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses Measurement of Credit Losses on Financial Instruments In December 2019, the FASB issued ASU 2019-12, Income Taxes Simplifying the Accounting for Income Taxes

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Summary of Significant Accounting Policies
Schedule of total net revenues by geographic region	The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following table (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ ​ 2022 ​ 2021 ​ Geographic Region ​ Amount Percent Amount Percent Americas* ​ $ 21,938 64.3 % $ 16,258 66.8 % ​ Europe, Middle East and Africa (EMEA) ​ 4,310 12.6 % 2,713 11.1 % ​ Asia Pacific (APAC) ​ 7,893 23.1 % 5,382 22.1 % ​ Total revenues ​ $ 34,141 100.0 % $ 24,353 100.0 % ​ ​ * The Company’s total revenues in the United States were $21.5 million and $16.0 million for the three months ended March 31, 2022 and 2021, respectively.

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2022
Property and Equipment, Net
Schedule of Property and equipment, net	Property and equipment, net consists of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 December 31, 2021 ​ Computer equipment and software ​ $ 16,134 ​ $ 14,163 ​ Software development costs ​ 6,072 ​ 4,866 ​ Leasehold improvements ​ 1,936 ​ 1,947 ​ Furniture and fixtures ​ 545 ​ 540 ​ Total property and equipment, cost ​ 24,687 ​ 21,516 ​ Less accumulated depreciation and amortization ​ (9,641) ​ (8,465) ​ Total property and equipment, net ​ $ 15,046 ​ $ 13,051 ​ ​

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Accrued Expenses and Other Current Liabilities
Schedule of accrued expenses and other current liabilities	Accrued expenses and other current liabilities consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 December 31, 2021 ​ Accrued compensation ​ $ 3,973 ​ $ 3,180 ​ Accrued expenses ​ 1,973 ​ 1,182 ​ Accrued taxes ​ 611 ​ 1,216 ​ Total accrued expenses and other current liabilities ​ $ 6,557 ​ $ 5,578 ​

Operating Leases and Service _2

Operating Leases and Service Agreements (Tables)	3 Months Ended
	Mar. 31, 2022
Operating Leases and Service Agreements
Schedule of future aggregate minimum rental payments	​ ​ ​ ​ ​ ​ Amount 2022 (nine months) ​ $ 3,478 2023 ​ 3,310 2024 ​ 2,385 2025 ​ 901 Total ​ $ 10,074 ​

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Stock-Based Compensation
Schedule of stock compensation expense	​ ​ ​ ​ ​ (in thousands) ​ Cost of revenues ​ $ 354 General and administrative ​ ​ 8,938 Sales and marketing ​ ​ 1,993 Technology and development ​ ​ 1,397 Total stock compensation expense ​ $ 12,682

Net Income (Loss) Per Class A_2

Net Income (Loss) Per Class A Common Share (Tables)	3 Months Ended
	Mar. 31, 2022
Net Income (Loss) Per Class A Common Share
Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share	​ ​ ​ ​ ​ ​ ​ ​ (in thousands, except per share amounts) Three Months Ended March 31, 2022 Numerator: ​ ​ ​ Net loss ​ $ (12,524) Less: Net loss attributable to non-controlling interests ​ ​ 5,259 Net loss attributable to Enfusion, Inc. ​ ​ (7,265) Adjustment to income (loss) attributable to common stockholders ​ ​ (716) Numerator for Basic Earnings per Share ​ $ (7,981) Denominator: ​ ​ ​ Weighted-average shares of Class A common stock outstanding ​ ​ 65,583 Vested shares of Class A common stock and RSUs ​ ​ 17,801 Weighted-average shares of Class A common stock outstanding--basic ​ ​ 83,384 Net loss per share of Class A common stock--basic and diluted ​ $ (0.10)
Schedule of effect of dilutive shares antidilutive	​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Three Months Ended March 31, 2022 Class B common stock ​ 47,471 Contingently issuable shares of Class A common stock ​ ​ 893 Restricted stock units ​ ​ 2,857 ​ ​ ​ 51,221

Principles of Consolidation and

Principles of Consolidation and Basis of Presentation - IPO and reorganization (Details)	3 Months Ended
	Mar. 31, 2022subsidiary
Number of wholly-owned subsidiaries.	3
Enfusion LLC
Ownership Percentage	58.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2022USD ($)customer	Mar. 31, 2021customer	Dec. 31, 2021customer
Revenue remaining performance obligation | $	$ 28.8
Major Customer | Revenues | Customer Concentration Risk
Number of customers	0	0
Major Customer | Accounts Receivable | Customer Concentration Risk
Number of customers	0		0
Minimum | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Remaining performance obligation satisfaction period	1 year
Maximum | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Remaining performance obligation satisfaction period	5 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Disaggregation of revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Total revenues	$ 34,141	$ 24,353
Revenues | Geographic Region
Disaggregation of Revenue [Line Items]
Total revenues	$ 34,141	$ 24,353
Total net revenues percent	100.00%	100.00%
Americas | Revenues | Geographic Region
Disaggregation of Revenue [Line Items]
Total revenues	$ 21,938	$ 16,258
Total net revenues percent	64.30%	66.80%
Europe, Middle East and Africa (EMEA) | Revenues | Geographic Region
Disaggregation of Revenue [Line Items]
Total revenues	$ 4,310	$ 2,713
Total net revenues percent	12.60%	11.10%
Asia Pacific (APAC) | Revenues | Geographic Region
Disaggregation of Revenue [Line Items]
Total revenues	$ 7,893	$ 5,382
Total net revenues percent	23.10%	22.10%
United States
Disaggregation of Revenue [Line Items]
Total revenues	$ 21,500	$ 16,000

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property and Equipment, Net
Total property and equipment, cost	$ 24,687	$ 21,516
Less accumulated depreciation and amortization	(9,641)	(8,465)
Total property and equipment, net	15,046	13,051
Computer equipment and software
Property and Equipment, Net
Total property and equipment, cost	16,134	14,163
Software development costs
Property and Equipment, Net
Total property and equipment, cost	6,072	4,866
Leasehold improvements
Property and Equipment, Net
Total property and equipment, cost	1,936	1,947
Furniture and fixtures
Property and Equipment, Net
Total property and equipment, cost	$ 545	$ 540

Property and Equipment, Net - N

Property and Equipment, Net - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Property and Equipment, Net
Property and equipment, net	$ 15,046		$ 13,051
Capitalized software development costs	1,200	$ 499
Depreciation and amortization expense	768	484
Amortization expense related to software development costs	408	$ 272
United States
Property and Equipment, Net
Property and equipment, net	$ 12,200		$ 10,400

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Accrued Expenses and Other Current Liabilities
Accrued compensation	$ 3,973	$ 3,180
Accrued expenses	1,973	1,182
Accrued taxes	611	1,216
Total accrued expenses and other current liabilities	$ 6,557	$ 5,578

Operating Leases and Service _3

Operating Leases and Service Agreements (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Total
2022 (nine months)	$ 3,478
2023	3,310
2024	2,385
2025	901
Total	10,074
Expense related to lease agreements	1,000	$ 902
Expense related to service agreements	268	$ 208
Minimum
Operating Leases and Service Agreements
Monthly base payments	6
Maximum
Operating Leases and Service Agreements
Monthly base payments	$ 16

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Commitments and Contingencies
Accruals for contingencies	$ 0	$ 0

Preferred Units Stockholders' E

Preferred Units Stockholders' Equity and Members' Deficit (Details)	1 Months Ended
	Oct. 31, 2021Voteshares	Mar. 31, 2022shares	Dec. 31, 2021shares
Class of Stock [Line Items]
Preferred stock authorized	100,000,000
Common Class A
Class of Stock [Line Items]
Common stock, shares authorized	1,000,000,000	1,000,000,000	1,000,000,000
Number of Voting Rights | Vote	1
Common Class B
Class of Stock [Line Items]
Common stock, shares authorized	150,000,000	150,000,000	150,000,000
Number of Voting Rights | Vote	1
Capital Units
Class of Stock [Line Items]
Stock exchange ratio	1,000,000

Stock-Based Compensation- Narra

Stock-Based Compensation- Narratives (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Oct. 31, 2021	Mar. 31, 2022
Management Incentive Plans
Total stock compensation expense		$ 12,682
Payment of tax withholding obligations for federal payroll taxes		1,200
Payment for employee payroll tax withholding obligations on stock-based compensation		$ 805
Options granted to employees		0
Common Class A | 2021 ESPP
Management Incentive Plans
Purchase price of common stock, percent	85.00%

Stock-Based Compensation- Equit

Stock-Based Compensation- Equity-Based Compensation (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Management Incentive Plans
Total stock compensation expense	$ 12,682
Restricted Stock Units And Class A Common Stock Vested
Management Incentive Plans
Unrecognized stock compensation expense	$ 41,100
Stock based compensation recognition period	2 years
Cost of revenues
Management Incentive Plans
Total stock compensation expense	$ 354
General and administrative
Management Incentive Plans
Total stock compensation expense	8,938
Sales and marketing
Management Incentive Plans
Total stock compensation expense	1,993
Technology and development
Management Incentive Plans
Total stock compensation expense	$ 1,397

Net Income (Loss) Per Class A_3

Net Income (Loss) Per Class A Common Share - Diluted net loss per common unit (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Numerator:
Net loss	$ (12,524)	$ 4,109
Less: Net loss attributable to non-controlling interests	5,259
Net loss attributable to Enfusion, Inc.	(7,265)	$ 4,109
Adjustment to income (loss) attributable to common stockholders	(716)
Numerator for Basic Earnings per Share	$ (7,981)
Denominator:
Weighted-average shares of Class A common stock outstanding	65,583
Vested shares of Class A common stock and RSUs	17,801
Weighted-average shares of Class A common stock outstanding--basic	83,384
Net loss per share of Class A common stock-basic	$ (0.10)
Net loss per share of Class A common stock- diluted	$ (0.10)

Net Income (Loss) Per Class A_4

Net Income (Loss) Per Class A Common Share - Dilutive shares (Details)	3 Months Ended
	Mar. 31, 2022shares
Antidilutive securities amount	51,221
Common Class B
Antidilutive securities amount	47,471
Contingently issuable shares of Class A common stock
Antidilutive securities amount	893
Restricted Stock Units
Antidilutive securities amount	2,857

Income taxes - Narratives (Deta

Income taxes - Narratives (Details)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Taxes
Effective tax rate (as a percent)	(1.21%)	6.42%
U.S. statutory tax rate (as a percent)	21.00%	21.00%

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2022
Related Party Transaction [Line Items]
Percentage of Entity's Share of Tax Benefits Under Tax Receivable Agreement	85.00%
Liability under the Tax Receivable Agreement	$ 74.7	$ 74.7
IPO
Related Party Transaction [Line Items]
Purchase of Common Units	5,526,608
Payments to acquire newly issued common units	$ 87.8

Subsequent Event (Details)

Subsequent Event (Details) - Subsequent Event	May 06, 2022shares
Subsequent Event
Common units exchanged (in shares)	1,401,818
Common units surrendered (in shares)	1,401,818
Increase in common units (in shares)	1,401,818
Common Class A
Subsequent Event
Stock issued (in shares)	1,401,818